Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096720 · ClinicalTrials.gov registry record · Phase 2
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00096720: Completed Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00096720 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096720, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
Interventions
- DRUG levodopa
- DRUG Mirapex (pramipexole)
- PROCEDURE [123I]ß-CIT and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00096720 record still lists
NCT00096720 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 3 interventions - of which levodopa is the first listed.
NCT00096720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096720 about?
NCT00096720 is a clinical study titled "Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease". Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New ...
What is the current status of trial NCT00096720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2004-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00096720?
The interventions under investigation include: levodopa (DRUG), Mirapex (pramipexole) (DRUG), [123I]ß-CIT and SPECT imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00096720?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096720's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia